Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aura Biosciences, Inc. - Common Stock (NQ:AURA)

6.340 +0.190 (+3.09%)
Streaming Delayed Price Updated: 11:29 AM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aura Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances ↗
Aura Biosciences (NASDAQ:AURA) is shifting its focus toward regulatory preparation and commercialization planning as enrollment in its registrational CoMpass study of bel-sar in early choroidal... 
Via MarketBeat
News headline image
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data ↗
Aura Biosciences (NASDAQ:AURA) executives outlined the company’s strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the... 
Via MarketBeat
News headline image
BETA Technologies, Starfighters Space And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-market trading after reporting fourth-quarter results. Other stocks declining in pre-market trading... 
Via Benzinga
Topics Stocks
News headline image
Recap: Aura Biosciences Q4 Earnings ↗
 
Via Benzinga
Stay updated with the stocks that are on the move in today's pre-market session. ↗
Via Chartmill
News headline image
Aura Biosciences Posts Q2 Cash Surge ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
4 Artificial Intelligence Stocks (That Aren't Nvidia) You Can Buy and Hold for the Next Decade ↗
These AI companies offer long-term growth potential and are worth holding for years to come. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Why United Airlines Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert ↗
U.S. stock futures were swinging between gains and losses on Thursday after snapping a three-day winning streak on Wednesday. Futures of major benchmark indices were mixed in premarket trading. Aiming... 
Via Benzinga
Topics Supply Chain World Trade
News headline image
Why Greenland Technologies Shares Are Trading Higher By Around 89%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Why Check-Cap Shares Are Trading Higher By Over 52%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Aura Biosciences' Bladder Cancer Candidate Demonstrates Tumor Shrinkage In Patients With High-Grade Disease ↗
Aura Biosciences released early Phase 1 trial data on bel-sar for non-muscle-invasive bladder cancer, showing promising clinical activity and a favorable safety profile. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
3 Small-Cap Stocks Ready to Deliver Significant Growth
Small-cap firms will have an easier time borrowing money for growth in a lower-interest-rate environment; these are a few companies poised for a breakout. 
Via MarketBeat
Topics Economy
News headline image
Aura Biosciences Touts Promising Data From Eye Cancer Candidate ↗
Aura Biosciences announced promising Phase 2 results for bel-sar in treating melanoma, achieving 80% tumor control. 
Via Benzinga
News headline image
AURA Stock Earnings: Aura Biosciences Beats EPS for Q2 2024 ↗
AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
AURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024 ↗
AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023 ↗
AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Aura Biosciences, Inc.
Via Business Wire
News headline image
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal Melanoma
From Aura Biosciences Inc.
Via Business Wire
News headline image
Over $13M Bet On This Energy Stock? Check Out These 4 Stocks Insiders Are Buying ↗
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades. 
Via Benzinga
News headline image
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences, Inc.
Via Business Wire
News headline image
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
News headline image
Why Aura Biosciences Stock Hit A New 52-Week Low Today ↗
Aura Biosciences Inc (NASDAQ: AURA) shares are trading lower by 34.7% to $7.18 Tuesday afternoon after the company announced pricing of its public offering of common st 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Sanmina Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers PaxMedica, Inc. (NASDAQ: PXMD) shares climbed 173.8% to $8.35. PaxMedica announced the publication of its autism spectrum disorder Phase 2 study results in the Annals of General Psychiatry. 
Via Benzinga
News headline image
Why Alteryx Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket ↗
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares surged 120.8% to $0.6450 in pre-market trading after the company reported a new strategic collaboration with Celest Therapeutics for the clinical... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.